The major purpose of the present study was to quantify correctly spliced CFTR transcripts in human nasal epithelial cells from cystic fibrosis (CF) patients carrying the splicing mutations c.580-1G4T (712-1G4T) and c.2657 þ 5G4A (2789 þ 5G4A) and to assess the applicability of this model in CFTR therapeutic approaches. We performed the relative quantification of CFTR mRNA by reverse transcription quantitative PCR (RT-qPCR) of these splicing mutations in four groups (wild type, CF-F508del controls, CF patients and CF carriers) of individuals. In addition, in vitro assays using minigene constructs were performed to evaluate the effect of a new CF complex allele c.[2657 þ 5G4A; 2562T4G]. Ex vivo qPCR data show that the primary consequence of both mutations at the RNA level is the skipping of their neighboring exon (6 and 16, respectively). The CFTR minigenes results mimicked the ex vivo data, as exon 16 skipping is the main aberrant transcript, and the correctly spliced transcript level was observed in a similar proportion when the c.2657 þ 5G4A mutation is present. In summary, we provide evidence that ex vivo quantitative transcripts analysis using RT-qPCR is a robust technology that could be useful for measuring the efficacy of therapeutic approaches that attempt to achieve an increase in CFTR gene expression.
INTRODUCTION
The splicing mechanism is a complex process regulated by intragenic and extragenic factors resulting in a mature mRNA, which is translated to cell protein undergoing the secretory pathway. Donor and acceptor sites and branch points in intronic sequences are essential for this process. 1 In addition, enhancer and silencer sequences in exons and introns act as splicing regulatory elements that also contribute to the exon definition. 2 Splicing factors binding with these specific signals can also affect the efficiency of the splicing process. 3 It has been reported in several genetic disorders that not only splicing mutations but also point mutations can activate/ inactivate these cis and trans elements thereby disrupting the synthesis or function of their encoded proteins. 4, 5 Aberrant transcripts that change the open reading frame are eliminated by the cell surveillance machinery resulting in variable levels of residual gene expression. In the end, splicing efficiency affects transcript abundance and consequently the amount of functional protein, the critical point which determines a pathological effect or a predisposition to disease. 6 Cystic fibrosis (CF; OMIM 219700) is a recessive genetic disorder due to deficient ionic transport in epithelial tissues. Most mutations in the CFTR gene (ABCC7; OMIM 602421) determine the total or partial loss of the CFTR channel function. Among these, 12% are splicing mutations (www.genet.sickkids.on.ca/cftr). Interestingly, a large and growing number of missense, synonymous and nonsense mutations have been found to disrupt the regulatory sequences involved in recognition of the exon, [7] [8] [9] and consequently, the proportion of splicing defects could be higher than that previously estimated. Changes in CFTR gene expression lead to phenotypic variability and low levels have been postulated as a predisposing factor to CFTR-related disorders. 8 Therefore, determining the amount of normal transcripts is essential to understand the complex relationship between genotype and phenotype.
The major purpose of the present study was to measure the levels of normal CFTR transcripts in human nasal epithelial (NE) cells from CF patients bearing the splicing mutations c.580-1G4T (712-1G4T, IVS5, class I mutation resulting in a major loss of CFTR protein) and c.2657 þ 5G4A (2789 þ 5G4A, IVS16, class V mutation with a partial loss of CFTR protein) and to detect differences in expression between genotypes. To this end, we have performed the relative quantification of CFTR mRNA of splicing mutations, in which a reduced CFTR expression level was unequivocally expected, by reverse transcription quantitative PCR (RT-qPCR), in order to evaluate the application of this model in CFTR therapeutic approaches. Furthermore, we provide new insights into a new complex allele involving the c.2562T4G SNP (exon 15) and the c.2657 þ 5G4A mutation.
In addition, in vitro assays using minigenes were performed. Finally, we evaluated the relationship between CFTR expression and the corresponding phenotype.
MATERIALS AND METHODS Individuals
Fifty-three individuals previously characterized 10, 11 were enrolled in this study. Samples were grouped considering four genotypes: (a) CF patients homozygous for p.Phe508del (CF-F508del), n ¼ 7; (b) compound heterozygous CF patients carrying one of the two different splicing mutations: the c.580-1G4T, n ¼ 4 [p.Phe508del (2), p.Gly542* (1), p.Ala399Asp (1) Table S1 ).
The study was approved by the ethics committee. All enrolled individuals, followed up in the same CF Unit, gave their written consent. Different CF clinical parameters were evaluated ( Table 1) .
Characterization of nasal epithelial cells
For details, Supplementary Information is available at the Eur J Hum Genet. website. Specific criteria were applied for inclusion of the RNA samples in order to reduce inter-sample variability: (a) RNA concentration Z50 ng/ml; (b) 260/ 280 nm Z1.90; and (c) RNA integrity number Z5.
RNA isolation and cDNA synthesis
Each RNA sample (500 ng) was reverse transcribed (RT) twice using the High Capacity cDNA Reverse Transcription kit and random primers (Applied Biosystem, Foster City, CA, USA).
Analysis of splicing mutations
See in silico and qualitative analysis in Supplementary Information.
qPCR
CFTR gene expression analysis was performed with Taqman assay-on-demand products on an ABI 7300 real-time PCR system (Applied Biosystem). Available Taqman assays for GUSB (Hs_99999908_m1) and ATP2B4 (Hs_00608066_m1) previously validated as reference genes 12 were used. Specific custom Taqman assays were synthesized for the two CFTR splicing mutations (Supplementary  Table S2 ). Only CFTR correctly spliced transcripts (CST) can be amplified using these assays (Supplementary Figure S2) . Triplicate reactions (20 ml each) from the two independent RT reactions were carried out for each sample/gene. Control samples such as 'no-RT' and 'no-RNA' were included to test for PCR and gDNA contamination, respectively. Furthermore, a calibrator sample was included in every run to correct for inter-run variability.
The raw Cq values were determined by using the SDS software v1.3.1 (Applied Biosystem), and normalization of data was performed by using the qBase Plus software (Biogazelle, Ghent, Belgium). 13 Mean values from both RT-qPCR for each sample and median expression for each group were considered for statistical analysis. Intra-group expression variability was assessed by the median absolute deviation (MAD).
Statistical analysis
Qualitative and quantitative clinical variables were analyzed using the Fisher's exact test and the two-tailed Student's t-test, respectively. Differences in expression between groups were assessed by Mann-Whitney test. All tests were performed using the SPSS 12.0 software (IBM, North Castle, NY, USA). Differences were considered statistically significant when Po0.05.
Minigenes construction and RNA analysis
The CFTR minigenes were produced using a 'sticky feet PCR' strategy to introduce CFTR introns (IVS14, IVS15 and IVS16) consecutively into the pCDNA5/FTR/CFTR mammalian expression vector carrying the complete wt-CFTR cDNA. Site-directed mutagenesis was used to introduce the mutations c.2657 þ 5G4A and c.2562T4G into the minigenes 14 (see Supplementary Information).
Protein analysis
CFTR detection was performed by western blot 15 (see Supplementary Information). 
Quantitative analysis of CFTR CSTs
Independent expression analysis of CFTR was carried out for the two splicing mutations in four different groups. The same controls, the wt (n ¼ 21) and the CF-F508del (n ¼ 7) groups, were analyzed for both mutations. In addition, expression analysis for the c.580-1G4T included CF carriers (n ¼ 3) and CF patients (n ¼ 4) and CF carriers and patients (n ¼ 9, each one) for the c.2657 þ 5G4A. In total, the CFTR expression analysis was performed in 35 (c.580-1G4T) and 46 (c.2657 þ 5G4A) individuals. CFTR gene expression was calculated relative to the expression of GUSB and ATP2B4 genes. 12 Previous to the analysis, several qualitycontrol parameters were taken into account. First, the inter-run and intra-run coefficients of variation (CVs) were calculated for all three genes analyzed. Intra-run CV ranged between 0.005 and 0.008 and inter-run CV between 0.014 and 0.026. PCR efficiency was also determined. Both CFTR assays showed an efficiency of 1.822; GUSB and ATP2B4 efficiencies were 1.888 and 1.817, respectively. The use of GUSB and ATP2B4 as suitable reference genes was determined by means of the gene expression stability value of multiple candidate genes (M) and the CV from normalized data. 16 The observed values were in agreement with the reference values Mo0.5, CVo0.200.
The c.580-1G4T mutation transcript analysis showed a marked decrease in the number of CSTs in those groups bearing the mutation, . Statistical analysis of expression data for both mutations showed significant differences between the wt group and those groups with the splicing mutations (P ¼ 0.032 for c.580-1G4T CF carriers; P ¼ 0.002 for c.580-1G4T CF patients; and Po0.001 for c.2657 þ 5G4A CF carriers and patients). A minor but significant difference was also found between the control groups, wt and CF-F508del, for the c.580-1G4T mutation (P ¼ 0.041; Figure 1a ).
It should be noted that CFTR gene expression level displayed a wide range between samples in the same group, irrespective of whether they were patients, carriers or controls, this finding being attributable to inter-individual variability.
When the CFTR gene expression in CF carriers and patients bearing the splicing mutations were compared with that in wt controls, the percentage of expression reduction was 34 and 60%, respectively, for c.580-1G4T mutation and 62 and 76%, respectively, for c.2657 þ 5G4A mutation (Figure 1c ). Thus, a more pronounced reduction of CFTR expression, in relative values, was observed in those samples bearing the c.2657 þ 5G4A mutation. Taking into account that the assays had similar PCR efficiencies, there have to be other reasons underlying these unexpected data.
Effect of the SNP c.2562T4G in the transcript level of samples bearing the c.2657 þ 5G4A mutation Contrary to what was expected before this study, we have found that the individuals with class V c.2657 þ 5G4A mutation have lower levels of CFTR CST compared with individuals bearing the class I c.580-1G4A mutation. To explain this result, we have considered the putative role of other sequence variants in exon processing. Different CFTR synonymous and non-synonymous SNPs are present in patients and controls in similar frequencies (data not shown), suggesting that their effect, if any, must be similar in all the groups analyzed. Surprisingly, a common SNP located in exon 15, c.2562T4G, showed allelic frequencies with statistically significant differences between those groups with the c.2657 þ 5G4A mutation and the two control groups (P ¼ 0.012). Thus, 26% alleles of wt controls and 14% alleles in the CF-F508del group showed the c.2562T4G SNP. Meanwhile, groups with the c.2657 þ 5G4A mutation had c.2562T4G frequencies that reached 50% in CF To determine whether other low-abundant transcripts are present but were not detected due to low sensitivity of the agarose gel, we performed a fluorescent RT-PCR semiquantitative analysis. The results confirmed the above data (see Supplementary Information). In addition, it revealed that the single-and double-mutant minigenes containing the c.2657 þ 5G4A only produce 29% ± 2.3 and 23% ± 0.4 of CST, respectively (compared with the total CFTR transcripts of each minigene) (Figure 3b ). The majority of the transcripts expressed by the single and the double mutants correspond to transcripts lacking exon 16 (63% ± 1.4 and 73% ± 1.6, respectively). The smaller percentage of transcripts, (8%±3.0 and 4%±1.2, respectively) correspond to transcripts lacking both exons 15 and 16.
We further analyzed the CFTR expression from these minigenes at the protein level by immunoblotting (Figure 4) . The results showed a reduction of 53% ± 15.6 and 65% ± 4.7 for single (lane 5) and double (lane 6) mutants, respectively (comparing with wt triple minigene; lane 3). In addition, a very faint band with a smaller molecular mass (B100 kDa) was detected on both mutant minigenes (lane 5 and 6). From the RNA studies, we have shown that both mutant minigenes produce two smaller transcripts, one skipping exon 16 and another skipping both exons 15 and 16 ( Figure 3 ). These transcripts would lead to truncated forms of CFTR with only 881 amino acids and 838 amino acids, respectively, and a molecular mass of 100 and 95 kDa, respectively. This prediction leads us to assume that the smaller faint protein band corresponds to these truncated forms. 
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Genotype-phenotype correlation Different clinical parameters were evaluated to determine the relationship between the amount of CFTR transcripts and the clinical outcome in CF patients. To provide a more robust data, other patients of the same CF Unit were included. Thus, statistical analysis was performed on 11 CF patients bearing the c.2657 þ 5G4A mutation (CF-splicing group) and 45 F508del homozygous patients (CF-F508del control group) ( Table 1 ). The small number of CF patients bearing the c.580-1G4T mutation prevented statistical analysis from being performed. However, their clinical parameters looked quite similar to the corresponding features of the CF-F508del group (Table 1) . The CF-splicing c.2657 þ 5G4A patients were mainly characterized by mild clinical CF manifestations in childhood; diagnosis was carried out in adulthood due to the presence of lung disease secondary to sinusitis, bilateral bronchiectasis and chronic bronchial infections by Pseudomonas aeruginosa. On the other hand, pancreatitis and pancreatic insufficiency were unusual. When comparing with the CF-F508del group, the CF-splicing group were older at the time of diagnosis as well as when the NE samples were collected (Po0.001), they showed a higher body mass index (Po0.037) and a better lung function (FEV1, Po0.0001; FVC, Po0.01; O 2 saturation Po0.02), and less bronchiectasis and also lower PI incidence (Po0.0001). However, CF-splicing patients showed a higher incidence of recurrent hemoptysis (Po0.001). Hemoptysis was massive in 4 out of 11 (36%) CF-splicing patients requesting arterial embolization (n ¼ 3) and surgery (n ¼ 1). Recurrent pancreatitis was also present in 18% of the CF-splicing group. Overall, these data suggest a less severe course of the disease, at least at its beginning, in the CF-splicing patients. Hence, although c.2657 þ 5G4A patients have a greater life expectancy, this class V mutation causes a severe chronic lung disease in older patients supporting our results from the expression analysis. In fact, one of these patients needed a lung transplant and another died at the age of 50 years. No significant differences between the two groups were observed concerning the number of times that patients needed hospitalization.
DISCUSSION
The CFTR gene has been found to be expressed at low levels in epithelial tissues 17 and also to show tissue specificity. 18, 19 Consequently, previous CFTR gene expression studies needed complex analysis methods and were mainly focused on the splicing efficiency of exon 9. 20, 21 Currently, these initial adverse conditions surrounding the CFTR expression analysis can be overcome using more sensitive tools, such as the RT-qPCR technology.
The pathological effect of many CFTR splicing variants is difficult to predict, particularly those in non-obvious regulatory elements or those that do not change the amino acid sequence. Here, the main aims were to assess the levels of CFTR CST in human NE cells from CF patients bearing splicing mutations, using the RT-qPCR technology, as a model to elucidate whether this technology could provide, in any mutation affecting gene transcript level, reliable data for CFTR transcript quantification that could be applied for further clinical purposes. Thus the study, including different genotypes, is focused on the analysis of class I and V CF splicing mutations to ensure that a reduction in CSTs will be observed. Taking into consideration that there is a correlation between the amount of CSTs and the abundance of functional protein, 22 the assays were designed to specifically quantify only the CSTs. In this way, we have prevented erroneous estimations as a consequence of different PCR efficiencies related to the size of the different spliced transcripts. Furthermore, complementary studies such as qualitative analysis of differently spliced transcripts and minigene expression analysis were performed.
The CFTR gene expression analysis has highlighted some interesting findings. First, we have observed a wide variability in CFTR expression among individuals from each group analyzed. A high variability in expression had already been reported in donor respiratory epithelium samples. 23 In addition, the variable NMD efficiency could contribute to this variability in CF patients with mutations generating a PTC. 24 The present and previous studies suggest the necessity of analyzing groups as large as possible for gene expression studies.
Contrary to what was expected, we have found a lower amount of CSTs in individuals with the class V mutation than in individuals with class I mutation, thus pointing out an apparent discrepancy between the genotype-phenotype relationship for these splicing mutations. We have found, at least, two factors contributing to these controversial data. First, concerning the genotype-phenotype relationship, different clinical features in class V patients (age at diagnosis, current age, etc.) indicated a milder phenotype compared with CF-F508del patients in agreement with previous reports 25, 26 and also with c.580-1G4T patients, although in this case statistical analysis was unavailable. Nevertheless, we have also observed some severe clinical complications in class V patients probably attributable to the aging process; we should keep in mind that the c.2657 þ 5G4A CF patients analyzed in this study are in the upper range of the life expectancy among CF patients. It had been previously reported that splicing efficiency decreases with age, 27 thus it is not unexpected that the more advanced age of class V patients contributes to the low transcript levels observed and their subsequent severe lung disease. To provide some light on the genotype-phenotype relationship, it would be interesting to perform a replicate study, including younger CF patients, for instance, from neonatal screening programs. Second, we have widely analyzed the DNA region surrounding the mutation c.2657 þ 5G4A to determine whether other genetic factors could contribute to the reduction in amounts of CSTs. We have identified a common c.2562T4G SNP in exon 15, probably in linkage disequilibrium with the c.2657 þ 5G4A mutation. Our data support that this common SNP leads to the skipping of exon 15, meanwhile the c.2657 þ 5G4A mutation is associated to the skipping of exon 16. Thus the c.2562T4G SNP further reduces the levels of CFTR CSTs in patients also carrying the c.2657 þ 5G4A, due to skipping of each one and both exons. This finding undoubtedly makes our results on CFTR gene expression more robust, as well as supplies further evidence that a synonymous coding SNP regulates the splicing efficiency. In fact, the controversial neutrality of synonymous SNPs had been reviewed recently. 28 Despite the c.2562T4G SNP and the c.2657 þ 5G4A mutation being largely known, this is the first study suggesting a linkage disequilibrium between them and demonstrating the relevant consequences at the RNA level of this c.[2562T4G; 2657 þ 5G4A] complex allele.
Minigene constructs have been largely used as a model to determine the effect of mutant alleles. However, their results have been corroborated by ex vivo analysis very few times due to unavailability of suitable samples. Here, we have performed CFTR minigene constructs to compare how close the results for CFTR transcript levels are in both ex vivo and in vitro approaches. The CFTR minigenes results mimicked the ex vivo data, as exon 16 skipping is the main AST and the CST level was observed in a similar proportion, when the c.2657 þ 5G4A mutation is present. However, we were unable to detect the AST that lack exon 15 resulting from the c.2562T4G mutant or the c.[2562T4G; 2657 þ 5G4A] double mutant, as was observed in the ex vivo analysis. In contrast, the ex vivo analysis was performed with some samples homozygous for the c.2562T4G SNP as well as primers specifically designed to detect the skipping of exons 15-16, probably forcing the detection of the ASTs that were very poorly represented.
Using the minigene strategy, we could analyze the impact of the CFTR variants at the RNA and protein level, which is not very easily feasible in ex vivo as CFTR protein detection requires a large amount of tissue. Analysis of the protein is of crucial importance to evaluate the impact of mutations on the amount of correctly processed CFTR.
The discrepancies observed between ex vivo and in vitro analysis in CFTR transcripts can be due to different factors. First, differences in CFTR expression can be due to the different cell types used in the two approaches; the human epithelial cells and the HEK cell line, as it is well known that the efficiency of alternative splicing is different among human tissues/cell types, probably determining the typical organ involvement in CF. 20, 29 Second, we compare ex vivo 'physiological conditions' in a limited individual series with the in vitro model in which the CFTR is highly overexpressed. It is also worth noting that we cannot use the versatility of minigene constructs when using the human physiological nasal cells, because in our study there is no CF patient/carrier bearing the splicing mutation without the SNP, suggesting linkage disequilibrium between both variants. In summary, different factors can explain these apparent controversial data without reducing the value of either approach, the minigenes model has been widely used to evaluate the mutant genes behavior, and also there is extensive evidence of the high sensitivity of RT-qPCR analysis in human tissues. In all, we believe that ex vivo analysis of human samples, despite its own limitations, provides the most accurate approach to determine what is happening in physiological conditions. However, when tissues samples are not available, the minigene approach is a good strategy to determine the effect of splicing mutations. The minigene strategy provides the advantage of allowing individual discrimination for each mutation effect (only one allele is present) and also protein analysis.
In conclusion, more attention should be given to the analysis of splicing mutations as many factors can influence the transcript processing and thus result in a less functional protein. Quantification of functional CFTR transcripts is important as the expression of fulllength CFTR RNA 410% of the levels found in normal individuals has been suggested to prevent the CF phenotype. 30 In this context, we postulate that RT-qPCR is a robust and reliable technology to offer the sensitivity necessary to evaluate in ex vivo studies the efficacy of those therapeutic approaches that attempt to achieve an increase in the CFTR gene expression.
